| Diabetes Mellitus
Novolog vs Levemir
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Insulin Diluting Medium For Novolog vs Levemir with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLevemir has a higher rate of injection site reactions vs Insulin Diluting Medium For Novolog based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Levemir but not Insulin Diluting Medium For Novolog, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Insulin Diluting Medium For Novolog
Levemir
At A Glance
SC injection
Pre-meal
Rapid-acting insulin analog
SC injection
Once or twice daily
Long-acting basal insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus Inject SC within 5-10 minutes before a meal into the abdominal area, thigh, buttocks, or upper arm; generally used with an intermediate- or long-acting insulin; may also be administered via continuous SC infusion pump or diluted to 0.05-1 unit/mL for IV infusion; individualize dose based on metabolic needs and blood glucose monitoring results.
Diabetes Mellitus (Type 1) Approximately one-third to one-half of the total daily insulin dose SC once or twice daily in combination with rapid-acting or short-acting insulin; initial total daily dose 0.2-0.4 units/kg in insulin-naive patients.
Diabetes Mellitus (Type 2) 10 units (or 0.1-0.2 units/kg) SC once daily in the evening or divided into a twice-daily regimen in patients inadequately controlled on oral antidiabetic medications or a GLP-1 receptor agonist.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to NOVOLOG or one of its excipients
- Episodes of hypoglycemia
- Hypersensitivity to insulin detemir or any excipient in LEVEMIR, including reactions such as anaphylaxis
Adverse Reactions
Most common (>=5%) Headache, accidental injury, nausea, diarrhea (type 1 diabetes); hyporeflexia, onychomycosis, sensory disturbance, urinary tract infection, chest pain, skin disorder, abdominal pain, sinusitis (type 2 diabetes)
Serious Severe hypoglycemia, generalized allergy/anaphylaxis, hypokalemia, lipodystrophy, peripheral edema
Postmarketing Localized cutaneous amyloidosis at injection site, medication errors with insulin substitution, hyperglycemia or hypoglycemia associated with amyloidosis-related injection site changes
Most common (>=5%) Upper respiratory tract infection, headache, pharyngitis, influenza-like illness, abdominal pain, hypoglycemia
Serious Severe hypoglycemia, anaphylaxis, generalized skin reactions, angioedema, bronchospasm, hypotension, shock, lipodystrophy, peripheral edema, hypokalemia
Postmarketing Medication errors with accidental administration of other insulins instead of LEVEMIR, localized cutaneous amyloidosis, hyperglycemia or hypoglycemia associated with injection into amyloidosis sites
Pharmacology
Rapid-acting human insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, with peak glucose-lowering effect 1-3 hours after SC injection and duration of action 3-5 hours.
Long-acting basal human insulin analog that regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production; prolonged duration of action is mediated by self-association of drug molecules at the injection site and albumin binding in the bloodstream.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Insulin Diluting Medium For Novolog
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
Levemir
- Covered on 5 commercial plans
- PA (7/12) · Step Therapy (1/12) · Qty limit (0/12)
UnitedHealthcare
Insulin Diluting Medium For Novolog
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Levemir
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Insulin Diluting Medium For Novolog
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Levemir
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Insulin Diluting Medium For Novolog.
No savings programs available for Levemir.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Insulin Diluting Medium For NovologView full Insulin Diluting Medium For Novolog profile
LevemirView full Levemir profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.